Triphendiol

Drug Profile

Triphendiol

Alternative Names: HMC; NV-196

Latest Information Update: 12 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novogen
  • Developer Marshall Edwards
  • Class Antineoplastics; Isoflavones
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Malignant melanoma; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 23 Dec 2010 No development reported - Phase-I for Solid tumours in Australia (IV)
  • 23 Dec 2010 No development reported - Phase-I for Solid tumours in Australia (PO)
  • 15 May 2008 Pharmacodynamics, adverse events & pharmacokinetics data from a phase Ia trial released by Marshall Edwards ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top